Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Condition(s):Chronic Graft vs Host DiseaseLast Updated:May 26, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Chronic Graft vs Host DiseaseLast Updated:May 26, 2022Recruiting
Condition(s):MyelofibrosisLast Updated:July 27, 2022Completed
Condition(s):Adherence, Patient; Adherence, TreatmentLast Updated:October 12, 2023Completed
Condition(s):Multiple MyelomaLast Updated:September 7, 2023Active, not recruiting
Condition(s):Cancer; Hematological MalignancyLast Updated:May 27, 2020Withdrawn
Condition(s):Recurrent Classical Hodgkin LymphomaLast Updated:April 6, 2020Completed
Condition(s):MyelofibrosisLast Updated:August 19, 2019Completed
Condition(s):Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Primary Myelofibrosis; Secondary MyelofibrosisLast Updated:March 20, 2024Recruiting
Condition(s):Essential ThrombocythemiaLast Updated:June 29, 2021Terminated
Condition(s):Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7Last Updated:January 23, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.